Content Type: Commentary & Opinion

Missed Opportunities on Emergency Remdesivir Use

March 16, 2026

Limitations on the Capability of the FDA to Advise

March 16, 2026

Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid Products

March 16, 2026

Tepid Steps on Drug Pricing

March 16, 2026

An Incomplete Prescription: President Trump’s Plan to Address High Drug Prices

March 16, 2026

Incentives for Drug Development—The Curious Case of Colchicine

March 16, 2026

Orphan Drug Designation and Exclusivity for “Same Drugs”

March 16, 2026

Will Inter Partes Review Speed US Generic Drug Entry?

March 16, 2026

Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-Up Studies to Ensure Safety and Effectiveness

March 16, 2026

Will Strict Limits on Opioid Prescription Duration Prevent Addiction? Advocating for Evidence-Based Policymaking

March 16, 2026

The Failure of Solanezumab—How the FDA Saved Taxpayers Billions

March 16, 2026

Breakthrough Medical Devices and the 21st Century Cures Act

March 16, 2026